English patients who have not responded to at least one other systemic therapy will soon be able to receive routine National Health Service (NHS) prescriptions for a targeted biologic for moderate to severe atopic dermatitis, the most common type of eczema.
Cost-effectiveness watchdog the National Institute for Health and Care Excellence (NICE) has recommended routine use of Sanofi’s (Euronext: SAN) Dupixent (dupilumab), alongside topical corticosteroids, in this indication in a Final Appraisal Determination (FAD).
The NICE recommendation represents a change of heart after the body issued earlier guidance not backing the treatment, which Sanofi is jointly developing with US biotech Regeneron Pharmaceuticals (Nasdaq: REGN).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze